June 13, 2016
CTI Clinical Trial & Consulting Services Announces Formation of Korean Subsidiary and Opening of Seoul Office
FOR IMMEDIATE RELEASE [Cincinnati, OH ~ June 13, 2016]
CTI Clinical Trial and Consulting Services (CTI), a multi-national, privately held, full-service contract research organization announces that it has opened an office in Seoul, Korea. The office is opened through the wholly-owned subsidiary, CTI Clinical Trial and Consulting Services Korea, Ltd. The company has opened more than a dozen offices over the past few years, with additional international expansion planned in Asia over the next 6-12 months. The company established their Pacific-Asia headquarters in Sydney, Australia several years ago.
“The expansion into Korea is part of efforts to increase capacity for clinical research in one of Asia’s fastest-growing countries for drug development,” according to Patrick Earley, Vice President, International. “We have been working with leading Korean academic medical centers for a number of years, as well as collaborating with innovative Korean biotechnology companies. This expansion will only further enhance the relationships and collaborations we have in the country.”
CTI has been working for nearly two decades in the drug development industry across North America, Europe, South America, Pac-Asia, and Africa, specializing in clinical research programs involving critically ill patient populations, and has more than 25 offices worldwide to serve nearly 120 pharmaceutical, biotechnology, and medical device clients.
About CTI Clinical Trial and Consulting Services
CTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organization (CRO), delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology, and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hepatology, cardiopulmonary, and pediatric populations. CTI also offers a fully integrated multi-specialty clinical research site that conducts phase I-IV trials. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. With clinical trial experience across 6 continents, CTI partners with research sites, patients, and sponsors to fulfill unmet medical needs. CTI is headquartered in Cincinnati, OH, with operations across North America, Europe, Latin America, and Asia-Pacific. For more information visit www.ctifacts.com